(MedPage Today) -- BERLIN -- Non-small cell lung cancer (NSCLC) patients starting immunotherapy were nearly twice as likely to be alive 3 years later if they got a COVID-19 vaccine around the time of treatment, a researcher reported here.
(MedPage Today) -- Chimeric antigen receptor (CAR) T-cell therapy for blood cancers appeared less toxic, and patients' hospital stays were days shorter, when they also had autoimmune disease before starting the treatment, a large…
Circulating tumor DNA (ctDNA)—genetic material shed from tumors into the bloodstream—may help risk-stratify patients with Stage 3 colon cancer by tailoring chemotherapy options after surgery based on risk of cancer recurrence, according to…
A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer, the second most common cause of cancer…
Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the cancer benefit from immunotherapy with atezolizumab compared to placebo whereas ctDNA-negative patients may…
A new multi-site study, published in JAMA, and co-led by researchers at the UNC Lineberger Comprehensive Cancer Center and Wake Forest University School of Medicine, has demonstrated that a direct-to-patient digital health program can…
(MedPage Today) -- BERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for patients with bone metastases from breast cancer, and also appeared to be safe in prostate…
An international team of researchers has uncovered a promising new avenue for treating colorectal cancer, the world's third leading cause of cancer-related deaths. By analyzing patient-specific genetic data, scientists identified a protein…
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with early-stage HER2…
Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients with Merkel cell carcinoma after surgery. Though recurrence rates overall weren’t significantly changed, the results…
(MedPage Today) -- BERLIN -- An antibody-drug conjugate targeting Trop2 significantly improved survival outcomes compared with platinum-based chemotherapy in pretreated patients with EGFR-mutated non-small cell lung cancer (NSCLC), a…
The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by researchers at The University of Texas MD…
A massive Veterans Affairs study has confirmed that nicotinamide may offer real protection against skin cancer. Patients who took the vitamin B3 derivative saw notable reductions in new cancer cases—especially squamous cell carcinomas. The…
Get latest articles and stories on Business at LatestLY. Mumbai (Maharashtra) [India], October 20: S.L. Raheja Hospital, Mahim - A Fortis Associate, has achieved a milestone in its clinical journey with the successful completion of its…
Scientists have found that preserving lymph nodes during cancer surgery could dramatically improve how patients respond to immunotherapy. The research shows that lymph nodes are essential for training and sustaining cancer-fighting T cells…